Acadia Pharmaceuticals (ACAD) FY2019 results: revenue $339 million, up 51.5% on the year
Acadia Pharmaceuticals Inc. (ACAD) reported revenue of $339 million for fiscal 2019, the year ended 31 December 2019, up 51.5% on the year before. Net income was -$235 million, and diluted earnings per share $-1.60. The figures are the company's own, from the 10-K it filed with the SEC on 27 February 2020.
Revenue
$339 million
+51.5% on the year
FY2012FY2019
Operating margin
-72.7%
-110.6% a year earlier
FY2012FY2019
Net income
-$235 million
FY2012FY2019
Diluted EPS
-$1.60
FY2012FY2019
this yearthe year beforeHover a bar for its figure.
The year in brief
Income statement (profit and loss)
$ million
FY2019
FY2018
FY2017
On the year
Last 8 years
Revenue
339
224
125
+51.5%
Cost of revenue
11.3
12.4
9.1
-8.3%
Gross profit
328
211
116
+55.0%
Gross margin
96.7%
94.5%
92.7%
Research and development
240
187
149
+28.4%
Selling, general and administrative
326
266
255
+22.5%
Operating income
-247
-247
-292
Operating margin
-72.7%
-110.6%
-234.1%
Pre-tax income
-234
-244
-288
Income tax
0.9
1.3
1.1
-30.3%
Net income
-235
-245
-289
Net margin
-69.4%
-109.6%
-231.7%
Diluted EPS
-$1.60
-$1.94
-$2.36
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2019
FY2018
FY2017
On the year
Last 8 years
Operating cash flow
-151
-167
-218
Capital expenditure
1.1
2.1
0.8
-46.3%
Free cash flow
-152
-170
-219
Free cash flow margin
-44.9%
-75.8%
-175.0%
Cash from investing
-166
-71.5
92.5
Cash from financing
372
307
31.2
+21.3%
Depreciation and amortisation
2.8
3.0
2.7
-8.0%
Share-based compensation
82.3
81.6
75.5
+0.9%
Shares outstanding at period end
155m
144m
124m
+7.9%
Balance sheet
$ million
FY2019
FY2018
FY2017
On the year
Last 8 years
Shareholders' equity
699
479
335
+45.9%
Debt
0.0
n/a
n/a
Operating lease liabilities
6.4
n/a
n/a
Other liabilities
77.7
61.1
49.2
+27.1%
Total liabilities and equity
783
540
385
+45.0%
Fixed assets
3.2
3.3
2.7
-3.9%
Intangible assets
2.6
4.1
5.5
-36.4%
Investments
508
339
272
+49.9%
Cash and equivalents
190
135
69.4
+40.8%
Receivables
35.8
26.1
17.3
+37.1%
Inventory
6.3
4.1
5.2
+55.8%
Other assets
37.9
29.2
12.4
+29.9%
Total assets
783
540
385
+45.0%
10-K for the year ended 31 December 2019, filed 27 February 2020: the filing.